Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

ABSTRACT: Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

PROVIDER: PRJNA807285 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18038231_1.fastq.gz	Fastqsanger.gz
	SRR18038231_2.fastq.gz	Fastqsanger.gz
	SRR18038232_1.fastq.gz	Fastqsanger.gz
	SRR18038232_2.fastq.gz	Fastqsanger.gz
	SRR18038233_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

Project description:Targeting DNA2 is synthetically lethal in myeloma cells that undergo metabolic adaptation and rely on oxidative phosphorylation to maintain survival after DNA damage activation.

2023-11-27 | GSE196766 | GEO

Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma.

Project description:DNA damage resistance is a major barrier to effective DNA-damaging therapy in multiple myeloma (MM). To discover mechanisms through which MM cells overcome DNA damage, we investigate how MM cells become resistant to antisense oligonucleotide (ASO) therapy targeting Interleukin enhancer binding factor 2 (ILF2), a DNA damage regulator that is overexpressed in 70% of MM patients whose disease has progressed after standard therapies have failed. Here, we show that MM cells undergo adaptive metabolic rewiring to restore energy balance and promote survival in response to DNA damage activation. Using a CRISPR/Cas9 screening strategy, we identify the mitochondrial DNA repair protein DNA2, whose loss of function suppresses MM cells' ability to overcome ILF2 ASO-induced DNA damage, as being essential to counteracting oxidative DNA damage. Our study reveals a mechanism of vulnerability of MM cells that have an increased demand for mitochondrial metabolism upon DNA damage activation.

| S-EPMC10853245 | biostudies-literature

SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

Project description:SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

| PRJNA687056 | ENA

Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma

Project description:Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma

| PRJNA1020864 | ENA

SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

Project description:SUMOylation, a posttranslational modification, regulates proteins by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a lysine (Lys) residue on target proteins. Here we use TAK-981, a selective SUMO-activating enzyme (SAE) inhibitor, to inhibit global SUMOylation in glucocorticoid sensitive and resistant multiple myeloma cell lines.

2021-12-31 | GSE163682 | GEO

A whole genome-screening strategy to identify DNA2 binding sites and genomic regions that require DNA2 for replication

Project description:We report that DNA2 predominantly bound to the centromeric α-satellite regions. The centromeric regions contained 58% of the DNA2-associated DNA, representing a 33.5-fold enrichment over genomic input. To define the under-replicated DNA regions in DNA2-null cells, we conducted whole-genome DNA sequencing of the under-replicated BrdU negative DNA. After normalization to genomic input DNA from the same cells, 12.9% of the peaks from the under-replicated DNA aligned with the centromeric DNA regions, representing an 8.5-fold enrichment. In addition, among the peaks that overlapped between the DNA2 pull-down and under-replicated regions, two thirds fell into the centromeric regions, representing a 48-fold enrichment.

2018-04-10 | GSE108619 | GEO

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma [ChIP-seq]

Project description:Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma [ChIP-seq]

| PRJNA1020862 | ENA

Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma [ATAC-seq]

Project description:Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma [ATAC-seq]

| PRJNA1020836 | ENA

Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma [RNA-seq]

Project description:Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma [RNA-seq]